Key regions: Germany, South Korea, France, United States, United Kingdom
The Anti-Coagulants market in India has been experiencing significant growth in recent years.
Customer preferences: One of the main drivers of this growth is the increasing prevalence of cardiovascular diseases in India. As a result, there is a growing demand for effective anti-coagulant drugs that can help prevent blood clots and reduce the risk of heart attacks and strokes. Patients in India are also becoming more aware of the importance of early detection and treatment of these conditions, leading to increased demand for anti-coagulant medications.
Trends in the market: In recent years, there has been a shift towards newer, more effective anti-coagulant drugs in India. These drugs offer several advantages over traditional anti-coagulants, such as a lower risk of bleeding and fewer dietary restrictions. As a result, they are becoming increasingly popular among patients and healthcare providers in India. Additionally, there has been an increasing trend towards the use of direct oral anti-coagulants (DOACs), which are more convenient and easier to administer than traditional anti-coagulants.
Local special circumstances: One of the unique challenges facing the anti-coagulants market in India is the high cost of these medications. Many patients in India are unable to afford these drugs, which can limit the growth of the market. Additionally, there is a lack of awareness and education among healthcare providers and patients regarding the appropriate use of anti-coagulant medications, which can lead to underutilization or misuse of these drugs.
Underlying macroeconomic factors: The growth of the anti-coagulants market in India is also being driven by broader macroeconomic factors, such as increasing healthcare spending and a growing middle class. As more people in India are able to access healthcare services and afford medications, the demand for anti-coagulant drugs is likely to continue to grow. Additionally, the Indian government has been taking steps to improve the healthcare system and increase access to affordable medications, which could further support the growth of the anti-coagulants market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
